Test Interpretation and Genomic Data Analysis
Evidence, not impressions
Variant interpretation follows structured frameworks that weigh population frequency, computational prediction, functional data, segregation, de novo status, and phenotype specificity. Know the evidence tiers: very strong, strong, moderate, and supporting, combined into pathogenic, likely pathogenic, uncertain significance, likely benign, and benign categories. Understand that benign evidence is used independently, and that a variant can move between categories as data accumulate.
Data sources include population databases with allele frequencies and constraint metrics, in silico predictors of splicing and protein effect, conservation, clinical variant databases, and the primary literature. For copy-number variants, interpret size, gene content, inheritance, and overlap with known benign or pathogenic regions.
Practical genomic analysis requires attention to coverage gaps, homologous regions and pseudogenes, mosaicism detection limits, and the difference between a true negative and an uninterpretable result.
Traps
Treating computational predictions as strong evidence; ignoring allele frequency in a founder or consanguineous population; over-interpreting a variant of uncertain significance as causative in a gene with high background variation; assuming a negative panel excludes a deletion when the platform did not assess copy number; and forgetting that a likely pathogenic result may need confirmation before irreversible clinical action.
Rule of thumb
A variant that is common in the general population is benign for a rare, highly penetrant Mendelian condition, regardless of how damaging it looks in silico. Check frequency first, then mechanism, then segregation, then prediction. This ordering prevents the most common interpretive errors on examinations.
Genetic Counseling: Process, Consent, and Psychosocial Care
Structure the encounter
Genetic counseling is a structured, nondirective process: gather history, assess understanding and psychosocial context, educate, support decision-making, and document. Pretest counseling must cover what will be tested and what will not, the range of possible results including variants of uncertain significance and secondary findings, implications for relatives, cost and insurance considerations, turnaround, and alternatives such as declining testing.
Post-test counseling translates results into meaning: diagnosis, prognosis, recurrence risk, surveillance, reproductive options, and referral. Informed consent is a process, not a signature, and is especially important for predictive testing, testing of minors, and research or biobank participation.
Psychosocial assessment includes coping style, family dynamics, cultural and religious beliefs, guilt, grief, and adaptation. Family communication is usually supported rather than performed by the counselor, and disclosure of a relative's results requires that relative's consent. Confidentiality has narrow exceptions, generally governed by law and institutional policy.
Traps
Returning a result without pretest counseling; assuming a patient wants every possible piece of information; recommending predictive testing for an adult-onset condition in a child when no childhood intervention exists; soliciting a relative's results without consent; and overlooking the emotional impact of a diagnosis in the rush to discuss management.
Rule of thumb
Before any test, ask three questions: what will we do with each possible result, who else may be affected, and what does the patient hope to learn? If the answer to the first is nothing changes, reconsider whether the test should be ordered now.
Risk Assessment and Communication: Bayesian Reasoning and Recurrence Risks
Quantify, then translate
Risk assessment combines pedigree analysis, inheritance patterns, and probability. Know baseline recurrence risks: autosomal recessive 25% for carrier couples, autosomal dominant 50% per offspring of an affected heterozygote, X-linked with a carrier mother 50% of sons affected and 50% of daughters carriers, and mitochondrial risks that depend on heteroplasmy and oocyte bottleneck dynamics.
Bayesian analysis updates a prior probability with conditional information such as unaffected offspring, normal test results, or age at onset. Set the prior from the pedigree, set conditionals for each hypothesis, multiply, and normalize.
De novo events require special care: a truly de novo variant carries a low but nonzero recurrence risk, commonly quoted as about 1% because of germline mosaicism, and higher for conditions with known high mosaicism rates. Consanguinity, founder effects, and assortative mating alter carrier risks.
Communication matters as much as calculation. Use natural frequencies rather than bare percentages, distinguish relative from absolute risk, check understanding with teach-back, and present options neutrally.
Traps
Applying a 50% risk to the siblings of a child with an apparently de novo dominant condition; ignoring germline mosaicism; confusing the risk of being a carrier with the risk of having an affected child; and quoting an age-independent penetrance to a patient whose age changes the interpretation.
Rule of thumb (worked example)
A woman's brother has an X-linked recessive disorder and her mother is an obligate carrier, so her prior carrier probability is 1/2. She has two unaffected sons. If she is a carrier, the chance both sons are unaffected is (1/2)² = 1/4; if she is not a carrier, it is 1. Posterior = (1/2 × 1/4) / [(1/2 × 1/4) + (1/2 × 1)] = 1/5.
Management, Treatment, Prevention, Ethics, Policy, and Professional Practice
Mechanism drives management
Treatment follows pathophysiology. Enzyme deficiency may respond to enzyme replacement, cofactor supplementation, or substrate restriction. Toxic accumulation is managed by dietary restriction or substrate reduction. Misfolded proteins may respond to pharmacological chaperones. Gain-of-function or toxic-RNA mechanisms may be addressed with antisense oligonucleotides or gene-based therapies. Many conditions have no disease-modifying therapy, and management then centers on surveillance, symptom control, and prevention of complications.
Know the surveillance rationale: early detection of treatable complications changes outcome, as with aortic imaging in Marfan syndrome, colonoscopy in Lynch syndrome and familial adenomatous polyposis, and tumor screening in Beckwith-Wiedemann syndrome. Prevention includes newborn screening, carrier screening, prenatal diagnosis, and preimplantation genetic testing.
Ethics and policy cover informed consent, autonomy, confidentiality, duty to recontact, secondary findings, research versus clinical testing, data privacy, insurance protections and their limits, equitable access, and resource stewardship. Professional practice includes accurate documentation, appropriate referral, laboratory accreditation standards, and recognizing the boundaries of one's expertise.
Traps
Assuming every diagnosis has a targeted therapy; conflating research testing with clinical testing; returning secondary findings without consent; and neglecting reproductive options when discussing prevention.
Rule of thumb
When asked what to do next for a newly diagnosed condition, work through four questions in order: is there a mechanism-based therapy, what surveillance prevents treatable complications, what reproductive options apply, and what ethical or access issues shape the plan?